Pill Power: The Economics of Monopolization Claims in Pharmaceutical Markets
While delayed generic entry cases dominated the pharmaceutical antitrust docket in the early part of this decade, there is now a broader mix of cases that evaluate competition in pharmaceutical markets for evidence of market power and harm to consumers. For example, are discounts tied to favorable formulary placement among a set of competing products anticompetitive or procompetitive? Are PBM exclusions and/or enforcement of network rules harmful? This panel will examine current trends in pharmaceutical antitrust, including reverse payments, product-hopping, pricing, monopoly leveraging, and potential issues with market definition in situations where specific indications or drug properties are at issue.